Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC 26271), vincristine (NSC 67574), and methotrexate (NSC 740)

J. Bitran, H. M. Golomb, R. K. Desser, M. Colman

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

During the past 3 yr, combination therapy for oat cell carcinoma of the lung has improved the dismal natural history of this disease, for which the median survival had been 3 mth. Recently, Eagan et al. reported a median survival of 9.5 mth in patients with oat cell carcinoma treated with radiotherapy and combination chemotherapy. The authors used a protocol similar to that of Eagan. Chemotherapy consisted of cyclophosphamide, vincristine, and methotrexate (CVM). They have confirmed the results reported by others in a group of 18 patients, 16 of whom had extensive bone or liver disease. The median survival of all patients treated was 9 mth. Responders (CR and PR) had a median survival of 11 mth which was attained with negligible toxicity. There was a very significant difference in survival between responders (CR and PR) and nonresponders: 11 mth versus 1.8 mth respectively (P=0.01). It is possible to predict which patients will respond, since objective response is usually seen within the first 2 cycles of chemotherapy.

Original languageEnglish
Title of host publicationCANCER TREAT.REP.
Pages221-223
Number of pages3
Volume60
Edition3
StatePublished - 1976
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Vincristine
Methotrexate
Cyclophosphamide
Radiotherapy
Survival
Drug Therapy
Bone Diseases
Small Cell Lung Carcinoma
Combination Drug Therapy
Liver Diseases

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Oncology

Cite this

Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC 26271), vincristine (NSC 67574), and methotrexate (NSC 740). / Bitran, J.; Golomb, H. M.; Desser, R. K.; Colman, M.

CANCER TREAT.REP.. Vol. 60 3. ed. 1976. p. 221-223.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{9131320fbb184ae6b636d03400dc085e,
title = "Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC 26271), vincristine (NSC 67574), and methotrexate (NSC 740)",
abstract = "During the past 3 yr, combination therapy for oat cell carcinoma of the lung has improved the dismal natural history of this disease, for which the median survival had been 3 mth. Recently, Eagan et al. reported a median survival of 9.5 mth in patients with oat cell carcinoma treated with radiotherapy and combination chemotherapy. The authors used a protocol similar to that of Eagan. Chemotherapy consisted of cyclophosphamide, vincristine, and methotrexate (CVM). They have confirmed the results reported by others in a group of 18 patients, 16 of whom had extensive bone or liver disease. The median survival of all patients treated was 9 mth. Responders (CR and PR) had a median survival of 11 mth which was attained with negligible toxicity. There was a very significant difference in survival between responders (CR and PR) and nonresponders: 11 mth versus 1.8 mth respectively (P=0.01). It is possible to predict which patients will respond, since objective response is usually seen within the first 2 cycles of chemotherapy.",
author = "J. Bitran and Golomb, {H. M.} and Desser, {R. K.} and M. Colman",
year = "1976",
language = "English",
volume = "60",
pages = "221--223",
booktitle = "CANCER TREAT.REP.",
edition = "3",

}

TY - CHAP

T1 - Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC 26271), vincristine (NSC 67574), and methotrexate (NSC 740)

AU - Bitran, J.

AU - Golomb, H. M.

AU - Desser, R. K.

AU - Colman, M.

PY - 1976

Y1 - 1976

N2 - During the past 3 yr, combination therapy for oat cell carcinoma of the lung has improved the dismal natural history of this disease, for which the median survival had been 3 mth. Recently, Eagan et al. reported a median survival of 9.5 mth in patients with oat cell carcinoma treated with radiotherapy and combination chemotherapy. The authors used a protocol similar to that of Eagan. Chemotherapy consisted of cyclophosphamide, vincristine, and methotrexate (CVM). They have confirmed the results reported by others in a group of 18 patients, 16 of whom had extensive bone or liver disease. The median survival of all patients treated was 9 mth. Responders (CR and PR) had a median survival of 11 mth which was attained with negligible toxicity. There was a very significant difference in survival between responders (CR and PR) and nonresponders: 11 mth versus 1.8 mth respectively (P=0.01). It is possible to predict which patients will respond, since objective response is usually seen within the first 2 cycles of chemotherapy.

AB - During the past 3 yr, combination therapy for oat cell carcinoma of the lung has improved the dismal natural history of this disease, for which the median survival had been 3 mth. Recently, Eagan et al. reported a median survival of 9.5 mth in patients with oat cell carcinoma treated with radiotherapy and combination chemotherapy. The authors used a protocol similar to that of Eagan. Chemotherapy consisted of cyclophosphamide, vincristine, and methotrexate (CVM). They have confirmed the results reported by others in a group of 18 patients, 16 of whom had extensive bone or liver disease. The median survival of all patients treated was 9 mth. Responders (CR and PR) had a median survival of 11 mth which was attained with negligible toxicity. There was a very significant difference in survival between responders (CR and PR) and nonresponders: 11 mth versus 1.8 mth respectively (P=0.01). It is possible to predict which patients will respond, since objective response is usually seen within the first 2 cycles of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0017101069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017101069&partnerID=8YFLogxK

M3 - Chapter

VL - 60

SP - 221

EP - 223

BT - CANCER TREAT.REP.

ER -